Kinnate Biopharma Inc. Common Stock
KNTE
KNTE was delisted on the 2nd of April, 2024.
58 hedge funds and large institutions have $54M invested in Kinnate Biopharma Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 16 increasing their positions, 22 reducing their positions, and 21 closing their positions.
900% more call options, than puts
Call options by funds: $30K | Put options by funds: $3K
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
19% less funds holding
Funds holding: 72 → 58 (-14)
27% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 22
55% less capital invested
Capital invested by funds: $121M → $54M (-$67.4M)
67% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$1.01M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$830K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$735K |
| 4 |
Renaissance Technologies
New York
|
+$404K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$347K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.04M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$1.49M |
| 3 |
HMC
Harvard Management Company
Boston,
Massachusetts
|
-$1.4M |
| 4 |
Millennium Management
New York
|
-$829K |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$819K |
KNTE Hedge Fund Activity: Q3 2023 in Review
58 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Kinnate Biopharma Inc. Common Stock (KNTE) for Q3 2023, worth a combined $54M — down 55% from $121M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of KNTE and 7 opened new positions — a net loss of 14 holders — while 22 trimmed existing stakes and 16 added.
The largest buyer was Citigroup, adding an estimated $1.01M. The largest seller was Fidelity Investments, exiting entirely with an estimated $2.04M sold.
- 58 institutional investors held Kinnate Biopharma Inc. Common Stock (KNTE) as of Q3 2023, down from 72 in Q2 2023.
- Funds reported $54M of Kinnate Biopharma Inc. Common Stock stock for Q3 2023, down 55% quarter-over-quarter.
- 7 funds opened new Kinnate Biopharma Inc. Common Stock positions in Q3 2023 and 21 closed out, a net change of -14 holders.
- The largest Kinnate Biopharma Inc. Common Stock buyer in Q3 2023 was Citigroup, an estimated $1.01M added.
- The largest Kinnate Biopharma Inc. Common Stock seller in Q3 2023 was Fidelity Investments, an estimated $2.04M sold.
Based on aggregated 13F filings for Q3 2023.